Clinical trials
Hepatocellular Carcinoma Resectable clinical trials
Below are recruiting hepatocellular carcinoma resectable clinical trials, each written for real people, not researchers. We’re tracking 207 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05534906Recruiting
Detecting very early liver cancer and tracking its natural course
This study looks at how well doctors can detect small, early liver cancer and then follow how it changes over time. It may help your care team choose the best next steps based on earlier, clearer detection.
Oxford, OxfordshireAges 18–100 - NCT05690048RecruitingPhase 2
Fecal transplant to help liver cancer respond to standard drugs
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT05718492Recruiting
Tested HAIC for liver cancer after prior immunotherapy
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
Guangzhou, GuangdongAges 18–75 - NCT05794048Recruiting
Study of blood and tumor features in liver and pancreatic cancers
This trial looks at a patient’s “metabolic profile” (how the body’s chemicals are used) in people with certain liver and pancreatic tumors. It may help doctors better understand these cancers and improve how they are evaluated for treatment.
ClichyAges 18 years+ - NCT05803928RecruitingPhase 1
Ablation plus lenvatinib and anti-PD-1 to prevent liver cancer return
This early-phase study tests whether adding medicines to ablation (heating/freezing to destroy liver tumors) can keep liver cancer from coming back. It’s for people whose liver cancer recurred after prior surgery/ablation but still fits specific criteria, with the goal of improving disease control.
Guangzhou, GuangdongAges 18–75 - NCT06031285RecruitingPhase 2
Perioperative immunotherapy plus TACE-HAIC for liver cancer with portal vein tumor thrombus
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
Guangzhou, GuangdongAges 18–75 - NCT06077591Recruiting
Genetic and organoid testing to guide cancer treatment
This trial uses advanced testing (genetic sequencing and lab-grown tumor models) to find the best treatment for people with advanced solid tumors that haven't responded to at least one standard treatment. The goal is to personalize therapy based on your tumor's unique features.
Hong Kong, N.T.Ages 18–100 - NCT06190665Recruiting
Bead type comparison for liver cancer TACE
This trial compares two types of tiny beads used in a liver cancer treatment called TACE to see which works better. If you have liver cancer that needs TACE and your liver is still working fairly well, you may be able to join.
Beijing, Beijing MunicipalityAges 18–80 - NCT06467799RecruitingPhase 2
New drug combo before and after surgery for high-risk liver cancer
This trial tests giving a liver-directed chemotherapy (HAIC) plus an immunotherapy (PD-1) before surgery, followed by more immunotherapy after surgery, for people with a specific type of liver cancer that has a high chance of coming back. The goal is to see if this approach can reduce the risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06553885RecruitingPhase 2
Study of enfortumab vedotin for advanced colorectal or liver cancer
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
Tampa, FloridaAges 18 years+ - NCT06593964Recruiting
TACE with a special gel vs standard beads for liver cancer
This trial compares a new gel-like treatment to standard beads for blocking the blood supply to liver tumors during TACE. It may be an option for patients with certain stages of liver cancer who cannot have surgery or other standard treatments.
NanjingAges 18–80 - NCT06689670Recruiting
Liver tumor ablation with a needle-based device
This trial tests a needle-based device that uses heat or cold to destroy liver tumors. It is for people with primary or secondary liver cancer who cannot have surgery or a transplant.
Topkapı, IstanbulAges 18–100 - NCT06725121RecruitingPhase 1/Phase 2
Radiation and immunotherapy for advanced liver cancer before transplant
This trial tests combining radiation therapy with immunotherapy (AtezoBev) before a liver transplant for advanced liver cancer. The goal is to see if this approach can shrink tumors and make transplant possible for more people.
London, OntarioAges 18–70 - NCT06735560Recruiting
PET scan with a tracer for liver, bile duct, or neuroendocrine tumors
This trial uses a special PET scan tracer (zirconium-labelled girentuximab) to see if it can find and track certain liver, bile duct, and pancreatic/intestinal neuroendocrine tumors. It may help doctors better understand your cancer and guide treatment decisions.
NantesAges 18 years+ - NCT06805552Recruiting
Sarcopenia and targeted therapy in liver cancer
This study looks at muscle loss in people with liver cancer who are receiving targeted therapy (TKIs). It aims to understand how muscle health affects treatment outcomes. You may qualify if you have intermediate or advanced liver cancer or earlier stage that hasn't responded to prior treatments.
BolognaAges 18 years+ - NCT06864195Recruiting
Breath test for liver cancer detection
This study tests a simple breath test to detect liver cancer and monitor liver health. It is looking for patients with liver cancer, liver cirrhosis, primary sclerosing cholangitis, or people with normal livers to see if the breath test can help tell the difference.
LondonAges 18 years+ - NCT06870942RecruitingPhase 2
Radiation therapy for liver cancer that progresses after first immunotherapy
This trial tests whether adding targeted radiation to liver cancer patients who have limited progression after initial immunotherapy can help control the disease. It is for people with hepatocellular carcinoma (HCC) whose cancer has started to grow in just a few spots after their first PD-1 treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06899854Recruiting
Collecting blood and tissue from patients with liver cancer
This study collects blood and tumor tissue samples from people with primary liver cancer who are starting their first treatment (systemic therapy or surgery). The samples help researchers learn more about these cancers and how to improve future treatments.
Pavia, PaviaAges 18–90 - NCT06914648Recruiting
Liver preparation before surgery study for certain liver cancers
This study tests a procedure called portal vein embolization (PVE) to help grow the healthy part of the liver before surgery. It may be an option for people with certain liver cancers who need more healthy liver tissue before their operation.
New Haven, ConnecticutAges 18 years+ - NCT06999707RecruitingPhase 2
Radiation plus immunotherapy for advanced liver cancer
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT06999694RecruitingPhase 2
Proton radiation with immunotherapy for liver cancer
This trial tests combining proton beam radiation with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer (HCC) that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT07001085Recruiting
Blood test to monitor liver cancer after surgery
This study uses a simple blood test to monitor tiny pieces of tumor DNA (ctDNA) in people with colorectal cancer that spread to the liver or with liver cancer (HCC), before and after liver surgery or transplant. It aims to help doctors detect cancer return earlier and guide treatment.
Warsaw, Masovian VoivodeshipAges 18–75 - NCT07062055RecruitingPhase 2
A study of combination therapy for advanced liver cancer with spread
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
Jinan, ShandongAges 18–70 - NCT07101237Recruiting
Precision diagnosis and treatment study for liver cancer
This study aims to improve how doctors diagnose and treat liver cancer by combining advanced imaging tests and genetic analysis. It may help in choosing the most effective treatment for each person.
BeijingAges 18–70
Hear when a new Hepatocellular Carcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma resectable?
- Yes. Clin2 currently lists 207 recruiting hepatocellular carcinoma resectable studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma resectable trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma resectable trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.